Elias Obeid, MD, MPH

- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Lab Staff
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Interim Chief, Division of Breast Medical Oncology
Assistant Professor, Department of Clinical Genetics
Director, Breast, Ovarian, and Prostate Cancer Risk Assessment
Specialties
Treatment Focus
Breast Cancer Treatment: particular interest in the treatment of triple-negative and hereditary breast cancers; Breast, Ovary, and Prostate Cancer Risk Assessment
Research Program
Treatment Philosophy
My philosophy in taking care of my patients is to spend as much time as possible listening to them. This allows me to know exactly what their fears and concerns are. I believe in working with our patients as a team to design the best plan of care for them, and when appropriate for their families if we identify a susceptibility to developing cancer in that family.
Educational Background
- MPH, University of Massachusetts, Amherst, Massachusetts, 2011
- MD, American University of Beirut School of Medicine, Beirut, Lebanon, 2000
Certifications
- Board Certified in Medical Oncology
- Board Certified in Internal Medicine
- Board Eligible in Hematology
- Pennsylvania Medical License
Memberships
- American College of Physicians (Fellow)
- Honor Society of Phi Kappa Phi
- American Society of Clinical Oncology
- American Association for Cancer Research (AACR)
Honors & Awards
- Main Line Today Top Doctors, 2019
- Abbott-Gonzalez Research Fellow Award, University of Chicago, 2012
- American College of Physicians - Connecticut (ACP-CT) Award for Volunteerism/Judge Research Awards, 2008
- First Annual Award: Service for Mission, Hospital of Saint Raphael, New Haven, CT, 2008
Research Program
Research Interests
- Genetic predisposition to breast cancer and ovarian cancer
- Genetic predisposition to prostate cancer
- Breast cancer: novel therapeutic interventions to improve outcomes for women with breast cancer and understanding the biology of the disease; immunotherapy
Lab Overview
The Risk Assessment Program at Fox Chase looks at your personal and possible inherited genetic factors that may put patients at higher possibility for getting cancer. Our team comprehensively examines the risk of an individual for different cancer types, including — but not limited to — breast cancer, ovarian cancer, gastrointestinal cancers, prostate cancer, and melanoma. Such information is helpful in order to understand the chances of getting cancer and decrease the likelihood of cancer or to detect cancer early. The Department of Clinical Genetics is built on the success of Fox Chase's Margaret Dyson Family Risk Assessment Program (now Risk Assessment Program), which Dr. Mary Daly began in 1991. A high-risk screening clinic was developed for individuals with a family history of breast or ovarian cancer.
As a member of the Breast Cancer Research team at Fox Chase, we offer our patients emerging therapies for breast cancer where patients have the opportunity to enroll in national clinical trials unique to Fox Chase that target breast cancer. I am interested in the design and implementation of trials focused on the development of those new therapies. In collaboration with other scientists, we work on understanding the biology of breast cancer through translational studies. My particular interest is in tumor microenvironment and immunotherapy.

Susan Montgomery, BSN, RN, GCN, OCN

Noele Myers, MSN, CRNP, FNP-BC, AOCNP
Additional Publications
Contact Information
Elias.Obeid@fccc.edu
Admin: Frank Ingram, 215-728-2792

Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Contact Information
Elias.Obeid@fccc.edu
Admin: Frank Ingram, 215-728-2792
Interim Chief, Division of Breast Medical Oncology
Assistant Professor, Department of Clinical Genetics
Director, Breast, Ovarian, and Prostate Cancer Risk Assessment
Specialties
Treatment Focus
Breast Cancer Treatment: particular interest in the treatment of triple-negative and hereditary breast cancers; Breast, Ovary, and Prostate Cancer Risk Assessment
Research Program
Treatment Philosophy
My philosophy in taking care of my patients is to spend as much time as possible listening to them. This allows me to know exactly what their fears and concerns are. I believe in working with our patients as a team to design the best plan of care for them, and when appropriate for their families if we identify a susceptibility to developing cancer in that family.
Education
Educational Background
- MPH, University of Massachusetts, Amherst, Massachusetts, 2011
- MD, American University of Beirut School of Medicine, Beirut, Lebanon, 2000
Certifications
- Board Certified in Medical Oncology
- Board Certified in Internal Medicine
- Board Eligible in Hematology
- Pennsylvania Medical License
Memberships
- American College of Physicians (Fellow)
- Honor Society of Phi Kappa Phi
- American Society of Clinical Oncology
- American Association for Cancer Research (AACR)
Honors & Awards
- Main Line Today Top Doctors, 2019
- Abbott-Gonzalez Research Fellow Award, University of Chicago, 2012
- American College of Physicians - Connecticut (ACP-CT) Award for Volunteerism/Judge Research Awards, 2008
- First Annual Award: Service for Mission, Hospital of Saint Raphael, New Haven, CT, 2008
Research Profile
Research Interests
- Genetic predisposition to breast cancer and ovarian cancer
- Genetic predisposition to prostate cancer
- Breast cancer: novel therapeutic interventions to improve outcomes for women with breast cancer and understanding the biology of the disease; immunotherapy
Lab Overview
The Risk Assessment Program at Fox Chase looks at your personal and possible inherited genetic factors that may put patients at higher possibility for getting cancer. Our team comprehensively examines the risk of an individual for different cancer types, including — but not limited to — breast cancer, ovarian cancer, gastrointestinal cancers, prostate cancer, and melanoma. Such information is helpful in order to understand the chances of getting cancer and decrease the likelihood of cancer or to detect cancer early. The Department of Clinical Genetics is built on the success of Fox Chase's Margaret Dyson Family Risk Assessment Program (now Risk Assessment Program), which Dr. Mary Daly began in 1991. A high-risk screening clinic was developed for individuals with a family history of breast or ovarian cancer.
As a member of the Breast Cancer Research team at Fox Chase, we offer our patients emerging therapies for breast cancer where patients have the opportunity to enroll in national clinical trials unique to Fox Chase that target breast cancer. I am interested in the design and implementation of trials focused on the development of those new therapies. In collaboration with other scientists, we work on understanding the biology of breast cancer through translational studies. My particular interest is in tumor microenvironment and immunotherapy.
Lab Staff

Susan Montgomery, BSN, RN, GCN, OCN

10 PATIENT COMMENTS